Nasdaq GlobeNewswire

Merus Announces Annual Meeting of Shareholders


UTRECHT, The Netherlands, May 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 24, 2017 at 8:00 am CET, at the Hilton Hotel Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, The Netherlands.

All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus website ( under "Financial Information."

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. Merus also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Forward Looking Statement
Except for the historical information set forth herein, this press release contains predictions, estimates and other forward-looking statements, including without limitation statements regarding the treatment potential of our bispecific antibody candidates.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; and our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts.

These and other important factors discussed under the caption "Risk Factors" in our Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Eliza Schleifstein
+1 973 361 1546

Kimberly Minarovich 
+1 646 368 8014

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Nitinat Provides Update on the Carscallen Gold Property19.3.2018 21:30Pressemelding

TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Further to its press release dated March 12, 2018 whereby Nitinat Minerals Corp. (the "Corporation") (TSX-V:NZZ) (Frankfurt:04U1) announced its option to acquire four (4) additional claims (collectively, the "Claims") abutting the western boundaries of the Corporation's current mining claims in Carscallen Township, Ontario (the "Carscallen Gold Property"), the Corporation is pleased to provide additional information pertaining to the Claims. The Corporation intends to implement an exploration program for the Claims to fully explore the potential of the Claims. The "preliminary technical appraisal" provided herein, along with the geophysics that the Corporation intends to undertake, will identify potential drill targets. The property encompassing the Claims is of particular interest in that surface exploration to date on the Claims has shown the existence of historic surface mining and sampling. The Corporation is currently assessing the most

New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09Pressemelding

Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in

Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial19.3.2018 12:00Pressemelding

The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018 CALGARY, Alberta, March 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The trial's first patient was enrolled on November 11th, 2015. The goal of the trial is to confirm the effect of Resverlogix' lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL). The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke. Secondary pre-specified endpoints in the trial will also examine renal function and MACE in patien

SolarWinds Places Highest on the Ability to Execute Axis in 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics19.3.2018 11:30Pressemelding

AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, placed highest on the ability to execute axis in the 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics1. This Gartner report evaluated 22 suppliers of Network Performance Monitoring and Diagnostics products. The firm's evaluation criteria for ability to execute included the following: product or service, overall viability, sales execution and pricing, market responsiveness and record, marketing execution, customer experience, and operations. Of all the vendors evaluated in the report, SolarWinds placed highest on the ability to execute axis. "For three years in a row, Gartner has positioned us as highest on the ability to execute axis in the Magic Quadrant for Network Performance Monitoring and Diagnostics. In our view, this result confirms our commitment to helping our customers manage their network operations with a powerful

Record High Number of Toll Transactions Cleared in Ireland in 201719.3.2018 10:51Pressemelding

ISSY LES MOULINEAUX, France, March 19, 2018 (GLOBE NEWSWIRE) -- The number of transactions processed through emovis's toll interoperability cloud-based hub in Ireland has reached a record high with over 50 million transactions cleared in 2017. Thanks to its toll interoperability solution, emovis is contributing to the improved mobility of millions of Irish drivers, by allowing them to travel seamlessly with just one toll tag across the whole country. As of January 2018, over 650,000 toll transponders are in use. With this new success, emovis demonstrates its leadership in designing and operating innovative mobility solutions that offer the best levels of service for road users in Ireland and throughout the world. About emovis was awarded the contract for managing Ireland's toll interoperability hub by the National Roads Authority (now Transport Infrastructure Ireland) in June 2013 following a competitive tender. As part of this contract, emovis designed, developed and is curre

Phenom People Set to Attend UNLEASH London19.3.2018 09:00Pressemelding

Candidate Experience Software Pioneer Attends UK Conference HORSHAM, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Phenom People, the leader in Talent Relationship Marketing (TRM), announced today that it will attend UNLEASH Conference & Expo on March 20-21 at the ExCel London. "We are no stranger to UNLEASH's strong turnout of highly passionate and forward-thinking individuals who are ready for the next big thing in technology. The inspiration and exchange of new ideas from the world's greatest thought leaders UNLEASH draws in every year, is what we look forward to the most," said Mahe Bayireddi CEO at Phenom People. "Our presence at this year's UNLEASH is vitally important as we continue to emerge as a global TRM leader with a growing list of European clients." UNLEASH, formerly HR Tech World, is held around the globe and was created to enhance the Future of Work by marrying technology with efficient business practices. UNLEASH London's speaker line-up consists of many big-league names inc

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom